IL135232A - 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids - Google Patents
21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoidsInfo
- Publication number
- IL135232A IL135232A IL13523298A IL13523298A IL135232A IL 135232 A IL135232 A IL 135232A IL 13523298 A IL13523298 A IL 13523298A IL 13523298 A IL13523298 A IL 13523298A IL 135232 A IL135232 A IL 135232A
- Authority
- IL
- Israel
- Prior art keywords
- oxidoprogesterone
- glucocorticoids
- hydroxy
- treating excess
- excess
- Prior art date
Links
- FIHWBGCIKMXLBI-NXMWLWCLSA-N (8s,9s,10s,13s,14s,17s)-17-acetyl-10-(hydroxymethyl)-13-methyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(CO)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 FIHWBGCIKMXLBI-NXMWLWCLSA-N 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- 229940037128 systemic glucocorticoids Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97116526A EP0903146A1 (en) | 1997-09-23 | 1997-09-23 | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
PCT/EP1998/006021 WO1999015181A1 (en) | 1997-09-23 | 1998-09-22 | 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids |
Publications (2)
Publication Number | Publication Date |
---|---|
IL135232A0 IL135232A0 (en) | 2001-05-20 |
IL135232A true IL135232A (en) | 2005-05-17 |
Family
ID=8227390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13523298A IL135232A (en) | 1997-09-23 | 1998-09-22 | 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids |
Country Status (13)
Country | Link |
---|---|
US (1) | US6303591B1 (xx) |
EP (2) | EP0903146A1 (xx) |
AR (1) | AR023008A1 (xx) |
AT (1) | ATE215373T1 (xx) |
AU (1) | AU738522B2 (xx) |
CA (1) | CA2303817C (xx) |
DE (1) | DE69804659T2 (xx) |
DK (1) | DK1033990T3 (xx) |
ES (1) | ES2172937T3 (xx) |
IL (1) | IL135232A (xx) |
PT (1) | PT1033990E (xx) |
WO (1) | WO1999015181A1 (xx) |
ZA (1) | ZA988674B (xx) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01011018A (es) | 1999-04-30 | 2002-05-06 | Pfizer Prod Inc | Moduladores del receptor glucocorticoide. |
US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
ES2271090T3 (es) * | 2000-09-18 | 2007-04-16 | Applied Research Systems Ars Holding N.V. | Metodo para la preparacion de 21-hidroxi-6,19-oxidoprogesterona (21oh-60p). |
PT1330468E (pt) * | 2000-09-18 | 2007-09-13 | Serono Lab | Análogos de enxofre de 21-hidroxi-6, 19-oxidoprogesterona ( 21oh-60p) para tratar excesso de glucocorticóides. |
EP1201660B1 (en) | 2000-10-30 | 2005-08-31 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
US8097606B2 (en) * | 2003-07-23 | 2012-01-17 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of catatonia |
EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
DK2054049T3 (en) | 2006-08-24 | 2016-08-01 | Univ Tennessee Res Found | SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF |
EP2576582B1 (en) | 2010-05-26 | 2019-09-18 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
CN104754939A (zh) | 2012-07-13 | 2015-07-01 | Gtx公司 | 用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法 |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
EP3265127B1 (en) | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
AU2016243625B2 (en) | 2015-03-30 | 2020-09-10 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
CA2994422A1 (en) | 2015-08-13 | 2017-02-16 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
ES2861524T3 (es) | 2016-01-19 | 2021-10-06 | Corcept Therapeutics Inc | Diagnóstico diferencial del Síndrome de Cushing Ectópico |
CA3065555A1 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
JP2022515528A (ja) * | 2018-12-28 | 2022-02-18 | パンダ コンサルティング エルエルシー | 短時間作用型選択的糖質コルチコイド受容体モジュレーター |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
CN1187053C (zh) * | 1997-10-06 | 2005-02-02 | 利兰·斯坦福青年大学托管委员会 | 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途 |
-
1997
- 1997-09-23 EP EP97116526A patent/EP0903146A1/en not_active Withdrawn
-
1998
- 1998-09-22 AT AT98956833T patent/ATE215373T1/de not_active IP Right Cessation
- 1998-09-22 DE DE69804659T patent/DE69804659T2/de not_active Expired - Fee Related
- 1998-09-22 DK DK98956833T patent/DK1033990T3/da active
- 1998-09-22 ES ES98956833T patent/ES2172937T3/es not_active Expired - Lifetime
- 1998-09-22 WO PCT/EP1998/006021 patent/WO1999015181A1/en active IP Right Grant
- 1998-09-22 PT PT98956833T patent/PT1033990E/pt unknown
- 1998-09-22 AU AU13341/99A patent/AU738522B2/en not_active Ceased
- 1998-09-22 EP EP98956833A patent/EP1033990B1/en not_active Expired - Lifetime
- 1998-09-22 ZA ZA988674A patent/ZA988674B/xx unknown
- 1998-09-22 CA CA002303817A patent/CA2303817C/en not_active Expired - Fee Related
- 1998-09-22 AR ARP980104727A patent/AR023008A1/es unknown
- 1998-09-22 IL IL13523298A patent/IL135232A/xx not_active IP Right Cessation
-
2000
- 2000-03-23 US US09/533,225 patent/US6303591B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE215373T1 (de) | 2002-04-15 |
IL135232A0 (en) | 2001-05-20 |
DK1033990T3 (da) | 2002-07-08 |
AR023008A1 (es) | 2002-09-04 |
PT1033990E (pt) | 2002-07-31 |
AU1334199A (en) | 1999-04-12 |
EP1033990A1 (en) | 2000-09-13 |
EP0903146A1 (en) | 1999-03-24 |
ES2172937T3 (es) | 2002-10-01 |
EP1033990B1 (en) | 2002-04-03 |
CA2303817C (en) | 2008-04-01 |
AU738522B2 (en) | 2001-09-20 |
ZA988674B (en) | 1999-06-28 |
DE69804659T2 (de) | 2002-10-02 |
CA2303817A1 (en) | 1999-04-01 |
DE69804659D1 (de) | 2002-05-08 |
WO1999015181A1 (en) | 1999-04-01 |
US6303591B1 (en) | 2001-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL135232A (en) | 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids | |
EP0874828A4 (en) | PAIN TREATMENT COMPOSITIONS | |
AP9600840A0 (en) | Treatment of ovarian estrogen dependent conditions | |
IL131484A0 (en) | Treatment of cardiomyopathy | |
AU7582398A (en) | Composition for treating skin conditions | |
ZA971709B (en) | Method of increasing testosterone | |
PL338082A1 (en) | Methods of treating obesity | |
GB9715295D0 (en) | Novel method of treatment | |
GB9712866D0 (en) | Novel method of treatment | |
GB9707693D0 (en) | Novel method of treatment | |
GB9725114D0 (en) | Treatment of pruritus | |
GB9715298D0 (en) | Novel method of treatment | |
GB9715306D0 (en) | Novel method of treatment | |
PL341667A1 (en) | Method of treating cooped | |
IL124419A0 (en) | Composition for treating pain | |
PL334803A1 (en) | Derivatives of imino-aza-antracyclinone for treating amyloidosis | |
EP1007041A4 (en) | COMPOSITION FOR TREATING PAIN | |
PL340430A1 (en) | Combination for treating aids | |
AU7247898A (en) | Composition for treating pain | |
PL335904A1 (en) | Application of 7alpha-methyl-17alpha-ethynylestrane derivative for treating arteriosclerosis | |
EP0912178A4 (en) | METHOD FOR TREATING THE HIGH PRESSURE | |
IL120254A0 (en) | Composition for treatment of acne | |
PL327430A1 (en) | Set of shaped components | |
PL313849A1 (en) | Beta-aminoesters of o-hydrobenzylamides | |
TW359161U (en) | Apparatus for safeguarding women against incontinenece of urine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
MM9K | Patent not in force due to non-payment of renewal fees |